



BSE : 500257	NSE: Lupin	REUTERS: LUPN.BO	BLOOMBERG: LPC IN
--------------	------------	------------------	-------------------

## LUPIN signs strategic agreement with FARMANGUINHOS, Brazil

**Mumbai, January 05, 2011:** Pharma Major, Lupin Ltd. announced today that it has entered into an agreement with Farmanguinhos, Brazil's largest PSU in Health Care and the Department of Health, Government of Brazil, for the supply of its 4 in 1 combination drug (Rifampicin + Isoniazide + Ethambutol + Pyrazinamide) for tuberculosis. Lupin will supply the product for the next 5 years and also provide Farmanguinhos with the desired support for the set up of its local manufacturing in future.

With this agreement between Lupin Ltd and Farmanguinhos in place, Farmanguinhos has entered into a commitment to Produce and supply the 4 in 1 combination drug to the Department of Health (Brazil), which will result in substantial savings for the government.

The 4 in 1 combination reduces the pill burden on the patient drastically, particular as the treatment lasts for at least 6 months. As per WHO, the treatment abandonment rate has fallen from 8% to only 5% due to this reduced pill burden provided by the combination drug. WHO estimates indicate that globally there are 9.2 million new cases each year resulting in 1.7 million deaths. In Brazil alone, it is estimated that approximately 57 million people are have already been infected by this disease with 83000 new cases annually and 4700 thousand deaths due to the illness.

Dr. Hayne Felipe, Director – Institute of technology (Farmanguinhos) described the event as “a big example of partnership for productive development. This agreement is special because it provides a solution for an illness of epidemiological proportion and importance”. The Agreement was signed in the presence of Brazil's Health Minister, Jose Gomez Temporao.

Commenting on the agreement, Mr. Vinod Dhawan, President – AAML & Business Development, Lupin, said "We believe that this agreement is a very important proactive step in providing comprehensive therapeutic care in the areas of conventional TB and MDR-TB, which are pandemic in nature. Lupin is a global leader for Anti TB drugs and has long been committed to developing and providing solutions to tackle and stem the growth of the disease globally. We feel that Lupin and Farmanguinhos together as partners are best suited to address this disease area in Brazil and the agreement further emphasizes our resolve to be an active participant in fighting these diseases in Brazil and Latin America which are markets of strategic focus for Lupin."

### **About Lupin Limited**

Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world. The Company today has significant market share in key markets in the Cardiovascular (prils and statins), Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAIDs therapy segments, not to mention global leadership positions in the Anti-TB and Cephalosporins. The Company's R&D endeavors have resulted in significant progress in its NCE program. The Company's foray into Advanced Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals.

Our Drugs and products reach over 70 countries in the world. Today, Lupin has the unique distinction of being the fastest growing top 10 Generics players in the two largest pharmaceutical markets of the world – The U.S (ranked 5th by prescriptions & growing at 51 %) and Japan (ranked 7th and growing at 23%). The company is also the fastest growing, top 5 pharmaceutical players in India (ORG IMS - March 2009) and the fastest growing Generic player in South Africa (ranked 6th and growing at 36 % YoY - IMS) as well as the Philippines.

For the Financial Year 2009-10, Lupin's Consolidated Revenues and Profit after Tax were Rs. 47,678 million (USD 1.1 Billion) and Rs. 6,816 million (USD 152 million) respectively. Please visit <http://www.lupinworld.com> for more information about Lupin Ltd.

Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Ltd. Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies. For more information, visit <http://www.lupinpharmaceuticals.com>.

**For further information please contact:**

Shamsher Gorawara  
Lupin Limited:  
Ph: +91 98 20 338 555  
Email: [shamshergorawara@lupinpharma.com](mailto:shamshergorawara@lupinpharma.com)

OR

Sonia Mansata  
Text 100 Public Relations  
Ph: +91 98 20 11 2481  
Email: [sonia.mansata@text100.co.in](mailto:sonia.mansata@text100.co.in)

*Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:*

*This release contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Many of these risks, uncertainties and other factors include failure of clinical trials, delays in development, registration and product approvals, changes in the competitive environment, increased government control over pricing, fluctuations in the capital and foreign exchange markets and the ability to maintain patent and other intellectual property protection. The information presented in this release represents management's expectations and intentions as of this date. Lupin expressly disavows any obligation to update the information presented in this release.*